Properties (49)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Cortex_Pharmaceuticals
NeurogesX |
| gptkbp:CEO |
gptkb:Ron_Cohen
|
| gptkbp:clinicalTrials |
Parkinson's disease
neurodegenerative diseases multiple sclerosis movement disorders spinal cord injury spasticity neuropathic pain |
| gptkbp:collaborations |
academic institutions
research organizations |
| gptkbp:employees |
approximately 200
|
| gptkbp:focusArea |
neurology
|
| gptkbp:founded |
2000
|
| gptkbp:founder |
gptkb:Ron_Cohen
|
| gptkbp:headquarters |
gptkb:Ardsley,_New_York
|
| https://www.w3.org/2000/01/rdf-schema#label |
Acorda Therapeutics
|
| gptkbp:innovation |
patient-centered solutions
neurological therapies clinical advancements |
| gptkbp:investmentFocus |
Venture capital
|
| gptkbp:keyFigures |
gptkb:Ampyra
Inbrija |
| gptkbp:leadership |
scientific expertise
business acumen regulatory knowledge |
| gptkbp:market |
gptkb:United_States
Europe Inbrija (2018) Ampyra_(2010) |
| gptkbp:mission |
improve lives of people with neurological disorders
|
| gptkbp:partnerships |
gptkb:Boehringer_Ingelheim
gptkb:UCB_Pharma |
| gptkbp:patentType |
gptkb:Ampyra
Inbrija |
| gptkbp:philanthropy |
community support
patient advocacy groups healthcare_initiatives |
| gptkbp:research_areas |
central nervous system disorders
|
| gptkbp:researchFocus |
clinical trials
drug development patient care |
| gptkbp:revenue |
$100 million (2020)
|
| gptkbp:stockSymbol |
ACOR
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:vision |
transformative therapies
|
| gptkbp:website |
www.acorda.com
|